Sermorelin

What it is

Sermorelin is a synthetic peptide reproducing the first 29 amino acids of human growth-hormone-releasing hormone (GHRH) — the shortest fragment that retains full GH-releasing activity. It binds the GHRH receptor on the pituitary and prompts the gland to release its own growth hormone in a natural, pulsatile pattern.

What it’s approved or studied for

Sermorelin has an unusual regulatory history. It was FDA-approved in 1997 and sold as Geref for assessing and treating growth-hormone deficiency in children. In 2008 the manufacturer discontinued the branded product for commercial reasons — importantly, the FDA later determined it was not pulled for safety or effectiveness problems. Today there is no FDA-approved sermorelin; it is available only through compounding pharmacies, and compounded sermorelin is not an FDA-approved finished drug. Its modern marketing has shifted almost entirely to adult “anti-aging” and wellness, a use it was never approved for.

What human evidence exists

The strongest evidence is for what earned its original approval: sermorelin reliably stimulates GH release in people with a working pituitary (Grade B), which made it useful for GHRH stimulation testing and pediatric GH-deficiency treatment. The popular adult claims — better body composition, sleep, energy, and slowed aging — do not rest on adequate controlled trials and are Grade U.

The major unknowns

Whether chronic sermorelin use benefits healthy adults, and whether it is safe over the long term in that population, is unknown (Grade U) — the historical evidence base was a supervised pediatric diagnostic and treatment setting, not open-ended adult wellness use. Because current supply is compounded, product strength and quality can vary between pharmacies.

Most important safety considerations

Injection-site reactions and hypersensitivity are the recognized short-term issues; the long-term safety of chronically stimulating GH in adults is not established. Any GH/IGF-1-raising therapy carries theoretical concern with active malignancy. It is prohibited in sport under WADA’s S2 category. Compounded status means it is not FDA-approved as a finished product. This page summarizes the research and regulatory record; it is not medical advice.